Immune checkpoint inhibitors (ICIs) that target cytotoxic T lymphocyte antigen 4,
programmed cell death-1, and PD-ligand 1 have revolutionized cancer treatment, achieving …

Abstract Background The US Food and Drug Administration (FDA) has approved several
immunotherapeutic drugs for cancer since 2010, and many more are still being evaluated in …

Immune checkpoint inhibitors (ICIs) are an effective therapy for various cancers; however,
they can induce immune-related adverse events (irAEs) as a side effect. Myocarditis is an …

Cardiac remodelling is characterized by abnormal changes in the function and
morphological properties such as diameter, mass, normal diameter of cavities, heart shape …

Abstract Immune-checkpoint inhibitors (ICIs), a unique antibody-based therapeutic strategy,
have revolutionized the treatment landscape of solid and hematological cancers. Despite …

Immune checkpoint inhibitors (ICIs) are monoclonal antibody antagonists, which can block
cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1/ligand-1 (PD-1/PD-L1) …

Background Immune checkpoint inhibitors (ICIs) have revolutionized the management of
multiple tumors, due to improved efficacy, quality of life, and safety. While most immune …

The introduction of immune checkpoint inhibitors have greatly improved clinical outcomes in
several cancer types, revolutionizing the management of a wide variety of tumors endowed …

The past decade has seen significant improvement in our understanding of tumor biological
features, which has led to use of anti-programmed-death 1 (PD-1) and anti-PD-ligand-1 (PD …

免疫检查点抑制剂(ICIs) 作为一种新型抗肿瘤药物, 在治疗多种恶性肿瘤中取得了前所未有的
疗效, 极大地改善了肿瘤患者的预后. ICIs 激活机体免疫细胞的抗肿瘤作用, 同时可导致免疫相关 …